FutureWiseResearch: Global Market Research Reports, USA, UK

Overview

Adalimumab Market Overview:

According to FutureWise analysis, the market for Adalimumab is expected to grow at a CAGR of 5.50% over the forecast period of 2023-2031.

Adalimumab is a subcutaneously administered biological disease regulator for treating rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor. Adalimumab was the fully human monoclonal antibody developed through phage display for clinical use in human patients, and it was approved in 2002 as a treatment for rheumatoid arthritis. Humira is the product name of the original adalimumab medication, and now there are five newer versions of adalimumab, known by the brand names Amgevita, Hyrimoz, Idacio, Imraldi, and Yuflyma.

Adalimumab has been approved with methotrexate for treating rheumatoid arthritis in the EU and USA, and validation for treating psoriasis, psoriatic arthritis, and ankylosing spondylitis is expected soon. Adverse reactions reported in trials include worsening or initiation of congestive heart failure, raised transaminases, medically significant cytopenias, including a lupus-like syndrome, and pancytopenia. Other adverse reactions like asthma, paresthesia in the leg and foot drop, and severe oral epithelial dysplasia. In grown-ups and children aged 12 years and older, this chronic skin condition is characterized by painful, small lumps under the skin. The medication also addresses posterior, non-infectious intermediate, and panuveitis in adults and children aged two years and older.

FutureWise Market Research has published a report that provides an insightful analysis adalimumab market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.

According to the analysis conducted by FutureWise research analysts, adalimumab market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

Major players included in the Adalimumab Market:

Croda International Plc
Clariant AG
AkzoNobel N.V
Ashland Inc
Evonik Industries
PolyOne Corporation
DuPont
Addcomp Holland
Lonza Group
PCC Chemax Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments in Adalimumab Market:

In July 2022, Sandoz announced that the United States Food and Drug Administration has accepted for review its Supplemental Biologics License Application for a high concentration composition of 100 mg/mL (HCF) of its biosimilar Hyrimoz. The application contains the indications of the reference medicine adalimumab not protected by orphan exclusivity, including rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn's disease, and plaque psoriasis.
In October 2021, The U.S. FDA announced the approval of first interchangeable biosimilar product for treating various inflammatory disorders. The biosimilar and interchangeable approval pathway was launched to help patients with critical medical conditions gain access to more treatment options. Cyltezo is the first interchangeable monoclonal antibody and the second interchangeable biosimilar medicine authorized by the FDA.

The growing prevalence of autoimmune diseases, such as psoriatic arthritis, plaque psoriasis, ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis, and Crohn's disease, is expected to anticipate the market's growth rate. Also, advanced treatment options among patients and healthcare providers and other biologic therapies drive the growth of the adalimumab market. For instance, in February 2022, Dr. Reddy's Laboratories launched a generic drug in the United States market. Moreover, ongoing research and clinical trials exploring the potential of adalimumab for new indications may further open opportunities for market expansion. Moreover, the growing incidence and approval of biosimilars in the market present a significant change in healthcare providers and favor these lower-cost alternatives to adalimumab. As biosimilars exhibit comparable effects and safety profiles to the reference drug, their increased adoption may lead to price competition and potential market share decline for adalimumab. Furthermore, high costs associated with manufacturing and the complex nature of molecules are expected to obstruct the market's growth rate. In developing regions, lack of comprehensive insurance coverage may restrict access to this medication for particular patients, particularly in budget-restricted areas. This limitation is likely to hinder the market expansion. Moreover, the effectiveness of adalimumab carries the risk of various adverse effects, ranging from moderate to severe, and safety concerns, primarily related to long-term use, may prompt healthcare providers and patients to explore alternative treatment options, impacting the growth of the adalimumab market.

Adalimumab Market Segmentation:

By Type

Adalimumab
Adalimumab Biosimilar

By Disease

Crohn’s disease
Psoriatic arthritis
Rheumatoid arthritis
Ulcerative colitis
Others

By End-User

Hospitals
Specialty Clinics
Others

By Region

North America
Europe
Asia-Pacific
Latin America
Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. The growing geriatric population and surging prevalence of rheumatoid arthritis in this region. The rising healthcare expenditure will also further propel the market's growth rate in this region. Rising awareness of disease remittance therapies among patients, rising prevalence of RA, and high public and private healthcare spending are stimulating the growth of the region. As per the World Health Organization, an estimated 54.4 million adults in the United States suffer from rheumatoid arthritis. Moreover, easy access to quality healthcare, favorable reimbursement policies, a strong clinical pipeline, and approval of novel drugs are projected to promote revenue growth in North America. For instance, in November 2021, Amgen said that it was seeking interchangeability status for its low-concentration adalimumab biosimilar (Amjevita).

Competitive Landscape:

Tier 1 players- established companies in the market with a major market share
Tier 2 players
Emerging players which are growing rapidly
New Entrants

FutureWise Key Takeaways:

Growth prospects
SWOT analysis
Key trends
Key data-points affecting market growth

Objectives of the Study:

To provide with an exhaustive analysis on the Adalimumab Market By Type, By Disease, By End User and By Region.
To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches

Flexible Delivery Model:

We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
The customization Mobility Care offered are free of charge with purchase of any license of the report
You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

1. Market Introduction
- 1. Objectives of the Study
  2. Market Definition
  3. Market Scope
  3.1. Years Considered for the Study
  3.2. Market Covered
  4. Currency
  5. Limitations
  6. Stakeholders
2. Research Methodology
- 1. Research Data
  1.1. Secondary Data
  1.1.1. Key Data from Secondary Sources
  1.2. Primary Data
  1.2.1. Key Data from Primary Sources
  2. Market Size Estimation
  3. Market Breakdown and Data Triangulation
  4. Assumptions for the Study
3. Executive Summary
- 1. Market Outlook
  2. Segment Outlook
  3. Competitive Insights
4. Adalimumab Market Variables, Trends and Scope
- 1. Market Lineage Outlook
  2. Penetration and Growth Prospect Mapping
  3. Industry Value Chain Analysis
  4. Cost Analysis Breakdown
  5. Technology Overview
  6. Regulatory Framework
  6.1. Reimbursement Framework
  6.2. Standards and Compliances
5. Market Overview
- 1. Market Dynamics
  1.1. Market Driver Analysis
  1.1.1. Increasing focus of Adalimumab Companies on Brand Protection
  1.1.2. Untapped Opportunities in Emerging Regions
  1.2. Market Restraint Analysis
  1.2.1. High Cost Associated with Implementation of Predictive Analysis
  1.3. Industry Challenges
  1.3.1. Presence of Ambiguous Regulatory Framework
6. Adalimumab Market Analysis Tools
- 1. Industry Analysis - Porter’s
  1.1. Supplier Power
  1.2. Buyer Power
  1.3. Substitution Threat
  1.4. Threat from New Entrants
  1.5. Competitive Rivalry
  2. Pestel Analysis
  2.1. Political Landscape
  2.2. Environmental Landscape
  2.3. Social Landscape
  2.4. Technology Landscape
  2.5. Legal Landscape
  3. Major Deals And Strategic Alliances Analysis
  3.1. Joint Ventures
  3.2. Mergers and Acquisitions
  3.3. Licensing and Partnership
  3.4. Technology Collaborations
  3.5. Strategic Divestments
  4. Market Entry Strategies
  5. Case Studies
7. Adalimumab Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. Adalimumab
  2. Adalimumab Biosimilar
8. Adalimumab Market, By Disease Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. Crohn’s disease
  2. Psoriatic arthritis
  3. Rheumatoid arthritis
  4. Ulcerative colitis
  5. Others
9. Adalimumab Market, By End-User Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. Hospitals
  2. Specialty Clinics
  3. Others
10. North America Adalimumab Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. U.S.A
  2.2. Canada
  2.3. Mexico
  3. Market Size (USD Million) Forecast for North America 2023-2031
11. Latin America Adalimumab Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Brazil
  2.2. Venezuela
  2.3. Argentina
  2.4. Rest of Latin America
  3. Market Size (USD Million) Forecast for Latin America 2023-2031
12. Europe Adalimumab Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Germany
  2.2. U.K
  2.3. France
  2.4. Italy
  2.5. Spain
  2.6. Russia
  2.7. Poland
  2.8. Rest of Europe
  3. Market Size (USD Million) Forecast for Europe 2023-2031
13. Asia Pacific Adalimumab Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Japan
  2.2. China
  2.3. India
  2.4. Australia and New Zealand
  2.5. ASEAN
  2.6. Rest of Asia Pacific
  3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031
14. Middle East and Africa Adalimumab Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. GCC
  2.2. Israel
  2.3. South Africa
  2.4. Rest of MEA
  3. Market Size (USD Million) Forecast for MEA 2023-2031
15. Market Share Analysis and Competitive Landscape
- 1. Global Landscape - Key Players, Revenue and Presence
  2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
  3. Global Emerging Companies
  4. North America - Market Share Analysis and Key Regional Players
  5. Europe - Market Share Analysis and Key Regional Players
  6. Asia Pacific - Market Share Analysis and Key Regional Players
  7. Global Key Player - Growth Matrix
16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
- 1. Croda International Plc
  1.1. Company Overview
  1.2. Product Portfolio
  1.3. SWOT Analysis
  1.4. Financial Overview
  1.5. Strategic Overview
  2. Clariant AG
  2.1. Company Overview
  2.2. Product Portfolio
  2.3. SWOT Analysis
  2.4. Financial Overview
  2.5. Strategic Overview
  3. AkzoNobel N.V
  3.1. Company Overview
  3.2. Product Portfolio
  3.3. SWOT Analysis
  3.4. Financial Overview
  3.5. Strategic Overview
  4. Ashland Inc
  4.1. Company Overview
  4.2. Product Portfolio
  4.3. SWOT Analysis
  4.4. Financial Overview
  4.5. Strategic Overview
  5. Evonik Industries
  5.1. Company Overview
  5.2. Product Portfolio
  5.3. SWOT Analysis
  5.4. Financial Overview
  5.5. Strategic Overview
  6. PolyOne Corporation
  6.1. Company Overview
  6.2. Product Portfolio
  6.3. SWOT Analysis
  6.4. Financial Overview
  6.5. Strategic Overview
  7. DuPont
  7.1. Company Overview
  7.2. Product Portfolio
  7.3. SWOT Analysis
  7.4. Financial Overview
  7.5. Strategic Overview
  8. Addcomp Holland
  8.1. Company Overview
  8.2. Product Portfolio
  8.3. SWOT Analysis
  8.4. Financial Overview
  8.5. Strategic Overview
  9. Lonza Group
  9.1. Company Overview
  9.2. Product Portfolio
  9.3. SWOT Analysis
  9.4. Financial Overview
  9.5. Strategic Overview
  10. PCC Chemax Inc.
  10.1. Company Overview
  10.2. Product Portfolio
  10.3. SWOT Analysis
  10.4. Financial Overview
  10.5. Strategic Overview
17. Pre and Post COVID-19 Impact
- 1. Positive influence on the healthcare industry
  2. The financial disruption of the manufacturing sector
  3. Impact of COVID-19 on emerging companies
  4. Significant mandates in the healthcare regulations initiated by administrations
  5. The overall economic slowdown of the developing and developed nations
18. FutureWise SME Key Takeaway Points for Client

Data Pack license: Data Pack license: $1250

Single user license: Single user license: $2850

Multi user license: Multi user license: $3850

Corporate license: Corporate license: $5000

Ask for Discount

Buy Now

Customize This Report

Partner

Report Overview

Table of Contents

List of Tables

List of figures

Overview

Table of Contents

Report Overview

Table of Contents

List of Tables

List of figures

Need Assistance

What you get

What's included

Our Clients